CytoMed Therapeutics Limited
GDTC · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $2,245 | $2,125 | $3,639 | $3,867 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $966 | $914 | $14 | $15 |
| Inventory | $0 | $0 | $614 | $653 |
| Other Curr. Assets | $0 | $0 | $97 | $103 |
| Total Curr. Assets | $3,211 | $3,039 | $4,394 | $4,669 |
| Property Plant & Equip (Net) | $2,731 | $2,585 | $2,382 | $2,531 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $57 | $54 | $68 | $72 |
| Long-Term Investments | $180 | $170 | $162 | $172 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $393 | $372 | $366 | $389 |
| Total NC Assets | $3,361 | $3,181 | $2,978 | $3,165 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $6,572 | $6,220 | $7,372 | $7,834 |
| Liabilities | – | – | – | – |
| Payables | $376 | $356 | $28 | $30 |
| Short-Term Debt | $30 | $28 | $28 | $29 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $132 | $125 | $116 | $123 |
| Total Curr. Liab. | $553 | $523 | $444 | $472 |
| LT Debt | $293 | $277 | $289 | $307 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $340 | $321 | $306 | $325 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $62 | $59 | $23 | $24 |
| Total Liabilities | $893 | $845 | $750 | $797 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $18,713 | $17,710 | $17,422 | $18,514 |
| Retained Earnings | -$13,442 | -$12,722 | -$10,872 | -$11,553 |
| AOCI | $350 | $331 | $15 | $16 |
| Other Equity | $0 | $0 | $0 | $0 |
| Total Equity | $5,620 | $5,319 | $6,565 | $6,976 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $60 | $56 | $57 | $60 |
| Total Liab. & Tot. Equity | $6,572 | $6,220 | $7,372 | $7,834 |
| Net Debt | -$1,922 | -$1,819 | -$3,323 | -$3,531 |